Immune thrombocytopenia (ITP) is the most common acquired thrombocytopenia after
chemotherapy-induced thrombocytopenia. Existing guidelines describe the management …

Chronic primary immune thrombocytopenia (ITP) can today benefit from multiple therapeutic
approaches with proven clinical efficacy, including rituximab, thrombopoietin receptor …

Immune thrombocytopenia (ITP) is commonly encountered in clinical practice. In 1996 the
American Society of Hematology published a landmark guidance paper designed to assist …

Bleeding manifestations in patients with immune thrombocytopenia (ITP) range from mild
skin bruises to life-threatening intracranial hemorrhage (ICH). Severe bleeding is distinctly …

Background Immune thrombocytopenia (ITP) is a heterogeneous acquired disorder
characterized by isolated thrombocytopenia whose exact pathogenesis is not yet clear …

Primary immune thrombocytopenia is an autoimmune disorder of unknown cause affecting
both children and adults. The low peripheral blood platelet count is caused by premature …

Immune thrombocytopenic purpura (ITP) is an autoimmune condition that affects nearly 1:
10,000 people in the world. It is traditionally defined by a platelet count of less than 100 x 10 …

Key Clinical Points Immune Thrombocytopenia Immune thrombocytopenia (ITP) is
diagnosed in patients with a platelet count below 100,000 per cubic millimeter in whom …

Promising reports of combination immunosuppression with high-dose dexamethasone and
rituximab for the treatment of primary immune thrombocytopenia (ITP) have recently …

Immune thrombocytopenia (ITP) is a common hematologic disorder that affects patient of all
ages, genders, and races. Initially known as idiopathic thrombocytopenic purpura, an …